Hemington Wealth Management Catalyst Pharmaceuticals, Inc. Transaction History
Hemington Wealth Management
- $371 Million
- Q3 2024
A detailed history of Hemington Wealth Management transactions in Catalyst Pharmaceuticals, Inc. stock. As of the latest transaction made, Hemington Wealth Management holds 2 shares of CPRX stock, worth $43. This represents 0.0% of its overall portfolio holdings.
Number of Shares
2Holding current value
$43% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding CPRX
# of Institutions
326Shares Held
94MCall Options Held
19.1KPut Options Held
51.1K-
Black Rock Inc. New York, NY18.7MShares$410 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.04MShares$176 Million0.0% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY6.23MShares$136 Million2.3% of portfolio
-
State Street Corp Boston, MA5.69MShares$125 Million0.0% of portfolio
-
Dimensional Fund Advisors LP Austin, TX3.02MShares$66.1 Million0.01% of portfolio
About CATALYST PHARMACEUTICALS, INC.
- Ticker CPRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 102,820,000
- Market Cap $2.25B
- Description
- Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthe...